Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29057552 | 1.00 | MAPT (0.66) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL765851 | 1.00 | MAPT (0.66) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL9663089 | 1.00 | MAPT (0.66) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL3249491 | 0.98 | MAPT (0.62) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL5101251 | 0.93 | HDAC3 (0.63) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL9665124 | 0.89 | HDAC3 (0.54) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL10653664 | 0.89 | MAPT (0.53) | MAPTRXFP1NAAAHDAC3HDAC1 | |
| SCHEMBL1197247 | 0.88 | MAPT (0.78) | MAPTRXFP1HDAC3HDAC1HDAC2 | |
| SCHEMBL456436 | 0.86 | FFAR4 (0.67) | FFAR4 | |
| Sebacic Acid SCHEMBL9311898 | 0.86 | HDAC11 (0.52) | MAPTRXFP1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497085-B1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | DOMPE FARM SPA (IT) | 2020-07-22 | — | — | EP | disclosed |
| EP-3281937-A1 | SULFONAMIDES AS GPR40- AND GPR120-AGONISTS | Dompé farmaceutici S.p.A. (IT) | 2018-02-14 | — | — | EP | disclosed |
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-8404896-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008070496-A2 | N- ( (3-BENZYL) -2, 2- (BIS-PHENYL) -PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885RXFP1 3476/4885NAAA 520/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885RXFP1 3476/4885NAAA 520/4885 |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FADS1, FAAH, SCD | MAPT 3956/4885RXFP1 2442/4885NAAA 64/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | MAPT 4114/4885RXFP1 3476/4885NAAA 520/4885 |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | MAPT 2531/4885RXFP1 2265/4885NAAA 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.